Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
Quince Therapeutics, Inc. (NASDAQ: QNCX) had its price target lowered by analysts at D. Boral Capital from $12.00 to $4.00. They now have a "buy" rating on the stock.
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia [Yahoo! Finance]